Alterity Therapeutics Limited (ASX: ATH) - ETF Exposure

Current share price for ATH : $0.240 0.025 (9.43%)⁺

Alterity Therapeutics Limited (ATH, formerly Prana Biotechnology Limited) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a clinical stage biotechnology company focused on neurodegenerative diseases. The company focusses to commercialise research into Parkinsonian movement disorders, Alzheimer disease, Huntington disease and other neurodegenerative disorders.

ATH General Information ⁺

ASX Code	ATH
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	54
ATH Share Price	$0.240
Day High	$0.260
Day Low	$0.235
Last Close	$0.265
ATH Share Price Movement	$0.03 ( 9.43% )

Prices as at 15:11, 27 Oct 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to ATH

Alterity Therapeutics Limited (ATH) is held across 4 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when ATH moves, funds like MQYM, MQDB and MQIO that hold it can move with it.

For more concentrated exposure, ETFs such as MQYM (Macquarie Global Yield Maximiser Active ETF) allocate about 0.8% to ATH , while the average exposure across all 4 ETFs that hold it is around 0.3% .

Top ETF holdings

Macquarie Global Yield Maximiser Active ETF (MQYM) ~ 0.8%
Macquarie Dynamic Bond Active ETF (Managed Fund) (MQDB) ~ 0.2%
Macquarie Income Opp Active ETF (Managed Fund) (MQIO) ~ 0.1%

Last updated: ETF data and holdings as at 11 October 2026

Own ATH directly or through an ETF?

How does holding Alterity Therapeutics Limited (ATH) shares directly compare to ETFs that include it?

	ATH Direct	MQYM ASX	MQDB ASX	MQIO ASX
Holdings	1 company	76 holdings	256 holdings	370 holdings
ATH Weight	100%	0.8%	0.2%	0.1%
Diversification	Single Stock	Broad	Broad	Broad
Annual Cost	Brokerage only	0.59% p.a.	0.61% p.a.	0.49% p.a.
Approx. Yield	0%	6.78%	3.74%	4.57%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not ATH's direct yield. Annual cost uses each ETF's MER.

ATH Exposure on $10,000 investment

How a $10,000 investment in Alterity Therapeutics Limited (ATH) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Alterity Therapeutics Limited (ATH)	Direct share	$0.240	-25%	-$2,500	$7,500
Macquarie Global Yield Maximiser Active ETF (MQYM)	Fixed Income - Global	$48.650	-0.14%	-$14	$9,986
Macquarie Dynamic Bond Active ETF (Managed Fund) (MQDB)	Fixed Income - Global	$10.440	0.19%	+$19	$10,019
Macquarie Income Opp Active ETF (Managed Fund) (MQIO)	Fixed Income - Global	$10.590	-0.09%	-$9	$9,991

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Alterity Therapeutics Limited (ATH) ETFs

4 ETFs hold Alterity Therapeutics Limited (ATH).

ETF	ATH Weight	MER	Yield
Macquarie Global Yield Maximiser Active ETF (MQYM)	0.8%	0.59%	6.78%
Macquarie Dynamic Bond Active ETF (Managed Fund) (MQDB)	0.2%	0.61%	3.74%
Macquarie Income Opp Active ETF (Managed Fund) (MQIO)	0.1%	0.49%	4.57%

View all 4 ETFs

Alterity Therapeutics Limited (ATH) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Alterity Therapeutics Limited (ATH) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Alterity Therapeutics Limited (ATH) price-sensitive announcements

ATH - $4.2M Options Underwriting Agreement Executed

Alterity Therapeutics Limited announced that it has executed an underwriting agreement wit

Alterity Therapeutics Limited (ATH)
31 Aug 2026 | 9:51 AM

ATH - Appendix 4E and 2026 Annual Report

Alterity Therapeutics Limited’s Appendix 4E and 2026 Annual Report for the financial year

Alterity Therapeutics Limited (ATH)
28 Aug 2026 | 3:33 PM

ATH - Granted New U.S. Composition of Matter Patent for ATH434

Alterity Therapeutics Limited announced the granting of a new U.S. composition of matter p

Alterity Therapeutics Limited (ATH)
12 Aug 2026 | 8:36 AM

ATH - Quarterly Activities/Appendix 4C Cash Flow Report

Alterity Therapeutics Limited issued its Q4 FY26 Quarterly Activities and Appendix 4C Cash

Alterity Therapeutics Limited (ATH)
30 Jul 2026 | 10:00 AM

Alterity Therapeutics Limited (ATH) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID	Health Care	$55	Proposed issue of securities - ATH	23 Oct 2026 4:20PM	$0.255	$0.240	fallen by 5.88%
Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID	Health Care	$55	Notification regarding unquoted securities - ATH	23 Oct 2026 10:29AM	$0.265	$0.240	fallen by 9.43%
Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID	Health Care	$55	Notification regarding unquoted securities - ATH	23 Oct 2026 10:28AM	$0.265	$0.240	fallen by 9.43%
Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID	Health Care	$55	Notice of Annual General Meeting/Proxy Form	21 Oct 2026 4:05PM	$0.255	$0.240	fallen by 5.88%
Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID	Health Care	$55	Changes to Managing Director Terms of Employment	21 Oct 2026 4:00PM	$0.255	$0.240	fallen by 5.88%
Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID	Health Care	$55	Alterity to Present at the Craig-Hallum Biotech Conference	19 Oct 2026 8:08AM	$0.310	$0.240	fallen by 22.58%

ATH Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2026A	-$23.40	-$11.10	-0.90%	0.00%	0.0%
2025A	-$14.35	-$11.20	-56.90%	0.00%	0.0%
2024A	-$19.12	-$26.00	-8.50%	0.00%	0.0%

ATH Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A
Alterity Therapeutics Limited (ATH)	$58M	-0.0089	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
CSL Limited (CSL)	$94,393M	0.7309	-0.4389	0.0602	12.1860	21.7178	20.4851	2.16%	2.17%	2.24%
Mesoblast Limited (MSB)	$2,310M	-0.4501	0.0000	0.0000	0.0000	0.0000	806.8182	0.00%	0.00%	0.00%
PYC Therapeutics Limited (PYC)	$1,752M	-0.3971	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$4,489M	-1.3893	0.0000	-0.5224	0.0000	155.1765	324.8768	0.00%	0.00%	0.00%

ATH Directors

Name	Position	Start Date
Mr Julian Barbaczy	Non-Executive Chairman, Non-Executive Director	21 Nov 2025
Mr Peter Ashley Marks	Non-Executive Director	29 Jul 2005
Mr Lawrence Bernard Gozlan	Non-Executive Director	8 Aug 2011
Ms Ann Cunningham	Non-Executive Director	17 Apr 2026

Alterity Therapeutics Limited (ATH) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
7 Apr 2025	GOZLAN, Lawrence	Buy	Indirect Shares	4,545,455	$0.011	$50,000.000
7 Apr 2025	MELTZER, Brian	Buy	Direct Shares	2,272,727	$0.011	$25,000.000
7 Apr 2025	MARKS, Peter	Buy	Indirect Shares	1,818,182	$0.011	$20,000.000

See all changes in directors' interest & trades for Alterity Therapeutics Limited (ATH) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

ATH Management

Name	Position
David Stamler	Chief Executive Officer
Abby Macnish Niven	Company Secretary

ATH Calendar of Events

Date	Event
27 August 2027	Report (Annual)
27 August 2027	Report (Prelim)
25 February 2027	Report (Interim)
20 November 2026	AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us